Federal contract award
HHSN272201600028C
IGF::OT::IGF - A BROAD-SPECTRUM ANTIBODY THERAPEUTIC AGAINST FLAVIVIRUS INFECTIONS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541711 |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $29.2M |
| Current contract value | $29.2M |
| Potential contract value / ceiling | $29.2M |
| Start date | Sep 19, 2016 |
| Current end date | Sep 30, 2022 |
| Potential end date | Sep 30, 2022 |
| Latest award activity | Sep 23, 2025 |
| Source loaded | Aug 15, 2026 |
Funding and modification history
Showing the latest 1 of 1 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 23, 2025 | P00022 | $-229.7K | THE PURPOSE OF THIS CONTRACT IS TO DEVELOP A MONOCLONAL ANTIBODY (MAB) AV-1 AS A SAFE INJECTABLE THERAPEUTIC. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.